EMP3 as a prognostic biomarker correlates with EMT in GBM

• Published in: BMC cancer Vol. 24; no. 1; pp. 89 - 14
• Main Authors: Li, Li, Xia, Siyu, Zhao, Zitong, Deng, Lili, Wang, Hanbing, Yang, Dongbo, Hu, Yizhou, Ji, Jingjing, Huang, Dayong, Xin, Tao
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 17.01.2024; BioMed Central; BMC
• Subjects: Analysis; Bioinformatics; Biological markers; Biomarkers; Brain cancer; Care and treatment; Cell growth; Cell migration; Cell proliferation; Central nervous system; Cholecystokinin; Correlation analysis; Datasets; DNA binding proteins; Epithelial membrane protein 3; Epithelial-mesenchymal transition; Gene expression; Genes; Genetic aspects; Genetic transcription; Genomes; Genomics; Glioblastoma; Glioblastoma cells; Glioblastoma multiforme; Glioma; Glioma cells; Gliomas; Isocitrate dehydrogenase; Malignancy; Medical prognosis; Membrane proteins; Nomograms; Performance evaluation; Polymerase chain reaction; Prognosis; Prognostic biomarker; Proteins; RNA; RNA sequencing; siRNA; Stem cells; Transcription factors; Transfection; Tumor cells; Tumors; Wound healing; China; United States > US; Japan; Epithelial membrane protein 3; Epithelial-mesenchymal transition; Glioblastoma; Prognostic biomarker

Glioblastoma (GBM) is the most aggressive malignant central nervous system tumor with a poor prognosis.The malignant transformation of glioma cells via epithelial-mesenchymal transition (EMT) has been observed as a main obstacle for glioblastoma treatment. Epithelial membrane protein 3 (EMP3) is sig...